Skip to main content
Year archive

ACTINOGEN MEDICAL LIMITED — 2019 filings

All 50 regulatory filings released by ACTINOGEN MEDICAL LIMITED (ACW) in 2019, sourced directly from the official regulator.

50 Filings
2019 Period
2019 filings (50)
Filing Released Lang
Review of 2019 and outlook 2 pages 175.7KB
Regulatory Filings
2019-12-17 English
Share Cancellation - Employee Share Plan 5 pages 348.9KB
Transaction in Own Shares
2019-12-12 English
Managing Director share loan repayment 5 pages 165.9KB
Director's Dealing
2019-11-26 English
ACW 2019 AGM Chairman's Address 3 pages 175.7KB
AGM Information
2019-11-24 English
Managing Director's AGM Presentation 28 pages 2.3MB
AGM Information
2019-11-24 English
Results of Annual General Meeting 3 pages 199.3KB
Declaration of Voting Results & Voting Rights Announcements
2019-11-24 English
Response to ASX Price Query 6 pages 279.7KB
Regulatory Filings
2019-11-19 English
September 2019 Quarterly Update 8 pages 315.5KB
Interim / Quarterly Report Q1 2019
2019-10-23 English
R&D Tax Incentive rebate received of $4.58 million 2 pages 147.7KB
Capital/Financing Update
2019-10-23 English
Notice of Annual General Meeting/Proxy Form 18 pages 799.6KB
AGM Information
2019-10-21 English
Annual Report to shareholders 90 pages 1.9MB
Annual Report FY 2019
2019-10-21 English
Cognitive improvement demonstrated with Xanamem 30 pages 2.5MB
Investor Presentation
2019-09-30 English
Actinogen Medical Conference Call 2 pages 138.9KB
Call Transcript
2019-09-29 English
Trading Halt 3 pages 239.2KB
Regulatory Filings
2019-09-26 English
Notification of 2019 Annual General Meeting Date 2 pages 136.9KB
AGM Information
2019-09-26 English
Appendix 4E & Annual Report 92 pages 1.9MB
Annual Report FY 2019
2019-08-15 English
Appendix 4G 8 pages 105.6KB
Governance Information
2019-08-15 English
June 2019 Quarterly Update 9 pages 251.0KB
Interim / Quarterly Report Q4 2019
2019-07-29 English
Clinical Development and Scientific Conference Update 2 pages 148.2KB
Capital/Financing Update
2019-07-02 English
Xanamen Clinical Development & Investor Update 33 pages 2.6MB
Investor Presentation
2019-06-25 English
Actingoen Medical participating in the BIO 2019 Convention 2 pages 150.6KB
Regulatory Filings
2019-06-02 English
XanaHES Trial to Continue 2 pages 150.3KB
Regulatory Filings
2019-05-28 English
Ceasing to be a substantial holder 2 pages 177.6KB
Major Shareholding Notification
2019-05-09 English
Ceasing to be a substantial holder from AEF 3 pages 423.0KB
Major Shareholding Notification
2019-05-07 English
Phase II Alzheimer's Disease Trial - results 3 pages 153.4KB
Capital/Financing Update
2019-05-06 English
Trading Halt 3 pages 241.1KB
Regulatory Filings
2019-05-02 English
Actinogen Updated Investor Presentation 47 pages 3.7MB
Investor Presentation
2019-04-30 English
March 2019 Quarterly Update 8 pages 308.7KB
Interim / Quarterly Report Q1 2019
2019-04-23 English
Change in substantial holding 3 pages 192.2KB
Major Shareholding Notification
2019-04-22 English
Lapse of Options 2 pages 142.7KB
Capital/Financing Update
2019-04-14 English
Appendix 3B 13 pages 163.2KB
Share Issue/Capital Change
2019-04-11 English
Appendix 3Y-Mr Malcolm McComas 2 pages 27.5KB
Director's Dealing
2019-04-11 English
New Clinical Development Opportunities for Xanamem 3 pages 149.4KB
Capital/Financing Update
2019-04-09 English
Actinogen Medical appoints new Non-Executive Director 2 pages 141.1KB
Board/Management Information
2019-04-03 English
Appendix 3X-Malcolm McComas 2 pages 69.6KB
Director's Dealing
2019-04-03 English
Appendix 3B 12 pages 160.3KB
Capital/Financing Update
2019-04-03 English
Cleansing Notice 1 page 106.1KB
Share Issue/Capital Change
2019-04-03 English
DSMB again reaffirms XanADu trial to continue without change 2 pages 142.1KB
Regulatory Filings
2019-03-25 English
Change in substantial holding 4 pages 252.7KB
Regulatory Filings
2019-03-21 English
Change in substantial holding (Replacement Form 604) 4 pages 282.9KB
Regulatory Filings
2019-03-21 English
Actinogen Updated Investor Presentation 44 pages 2.7MB
Investor Presentation
2019-03-20 English
Appendix 3B 12 pages 157.9KB
Capital/Financing Update
2019-03-18 English
Becoming a substantial holder 4 pages 248.3KB
Major Shareholding Notification
2019-03-13 English
Amended-Notification of Expiry of Listed Options 2 pages 192.6KB
Capital/Financing Update
2019-03-03 English
Notification of Expiry of Listed Options 2 pages 162.2KB
Share Issue/Capital Change
2019-02-26 English
Appendix 4D & Half-Year Financial Statements 24 pages 692.8KB
Interim / Quarterly Report H1 2019
2019-02-21 English
1st participant dosed in important new Xanamem study-XanaHES 2 pages 145.2KB
Regulatory Filings
2019-02-10 English
Appendix 3B 12 pages 160.3KB
Capital/Financing Update
2019-02-03 English
December 2018 Quarterly Update 8 pages 248.9KB
Interim / Quarterly Report Q2 2018
2019-01-28 English
ACW Presents at SACHS Neuroscience Forum during JPM Week 40 pages 2.6MB
Investor Presentation
2019-01-06 English